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Poor prognosis in Pneumococcal meningitis may be associated
with high pneumolysin levels in cerebrospinal ﬂuid (CSF).
In patient samples we showed that pneumolysin levels in CSF
remained high after 48 hours in nonsurvivors of meningitis
compared with survivors. Selective antipneumolysin treatment
may present a novel therapeutic option.
Streptococcus pneumoniae accounts for 50% of bacterial men-
ingitis in patients worldwide, carrying a 20% mortality rate in
Europe and 50%–60% in sub-Saharan Africa, with up to half
of the survivors left with serious neurological sequelae [1, 2].
Streptococcus pneumoniae expresses a range of protein virulence
factors associated with colonization of mucosal surfaces and
subsequent tissue invasion [3]. Virulence factors include pneu-
molysin (Ply) and neuraminidase (NanA); Ply is directly asso-
ciated with neuronal damage [4]. Damage to host tissue is
mediated either directly by bacterial proteins or indirectly via
the host inﬂammatory response [5]. Pneumolysin concen-
trations in cerebrospinal ﬂuid (CSF) in an animal model reach
20 ng/mL
21, a similar concentration to levels found in the CSF of
pneumococcal meningitis patients, which were 1–180 ng/mL [4].
Early antibiotic treatment improves the clinical outcome
in meningitis [6, 7]. Dexamethasone given as an adjuvant is
beneﬁcial in adults with acute pneumococcal meningitis in
developed healthcare settings [8] but not in middle- and low-
income countries [1]. We tested the hypothesis that persistent
pneumococcal protein in CSF might be associated with poor
outcome, despite antibiotic therapy.
METHODS
Sample Population
We previously recruited 465 patients with bacterial meningitis
to a double-blinded, randomized, placebo-controlled trial of
dexamethasone antibiotic adjuvant therapy [2]. Inclusion cri-
teria in that study were a clinical suspicion of bacterial menin-
gitis and positive cerebrospinal ﬂuid on microscopy (deﬁned
as organisms seen on Gram stain or .100 white cells/mm
2,o f
which .50% were neutrophils). CSF protein and glucose were
semiquantitated using urine dipsticks [9]. Patients were ad-
ministered ceftriaxone (2 g intravenously or intramuscularly
twice daily for 10 days) and randomized to receive either dexa-
methasone or placebo at the time of antibiotic administration.
CSF samples were taken prior to antibiotic administration on
the day of admission, and a second CSF sample was taken after
48 hours of antibiotic therapy in a small subset of patients in
whom this was indicated either clinically or for drug level
monitoring. Paired samples of CSF were stored at 280C. This
study was approved by the Liverpool School of Tropical Medi-
cine Research Ethics Committee and the College of Medicine
Research Ethics Committee of the University of Malawi.
Quantification of Ply and NanA
Ply and NanA levels in CSF samples were assayed using
standard Western blot. In brief, samples were separated by
sodium dodecyl sulphate–polyacrylamide gel electrophoresis
in a 1:5 dilution using phosphate-buffered saline and trans-
ferred to nitrocellulose membranes. Blots were blocked
overnight with 5% skimmed milk (Sigma) and incubated with
in-house anti-Ply and anti-NanA immunoglobulin G. For
quantiﬁcation, serial dilutions of puriﬁed Pdb (pneumolysin
toxoid derivative) and NanA were included on all immunoblots.
The initial concentration of Pdb was 1.2 mg/mL and NanA was
0.14 mg/mL; standard curves were constructed using band
densitometry for each serial dilution and compared with band
density in CSF samples (Quantity One software). Densitometry
of the ﬁlms was performed with Bio-Rad GS-700 imaging
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BRIEF REPORT d CID 2012:54 (1 March) d 701Figure 1. A and B, Concentrations of pneumococcal proteins pneumolysin (Ply) and neuraminidase A (NanA) in the cerebrospinal fluid (CSF) of patients
with proven meningitis compared with controls. The lower limit of detection was 2 ng/mL for Ply and 10 ng/mL for NanA. C and D, Concentrations of
pneumococcal proteins Ply and NanA in the CSF of patients with proven meningitis comparing samples taken from survivors and nonsurvivors at
admission and 48 hours. The lower limit of detection was 2 ng/mL for Ply and 10 ng/mL for NanA. E, Bacterial load of Streptococcus pneumoniae in the
CSF of patients with proven meningitis comparing survivors and nonsurvivors at admission and 48 hours.
702 d CID 2012:54 (1 March) d BRIEF REPORTdensitometer (Bio-Rad). Ply was detected as a band at 53 kDa
and NanA at 108 kDa, respectively. Densitometry results were
analyzed and concentrations of antigen levels were calculated in
micrograms per milliliter for NanA and milligrams per milli-
liter for Ply per CSF sample.
Quantification of Bacterial Load
Toextract pneumococcalDNA,100 lLofCSF wasremovedand
subjected to a lysozyme-buffer digestion protocol (20 mmol/L
Tris.Cl pH 8.0, 2 mmol/L EDTA, 1.2% Triton-X-100, 100 lL
of 103 lysozyme, and 10 lLo f1 0 3 lysostaphin), incubated
for 1 hour at 56C. DNA was extracted using Qiagen mini
blood and tissue kits (Qiagen, Germany). Pneumococcal
standards for real-time polymerase chain reaction (PCR) were
created using a known number of copies of synthetic autolysin
gene (LytA) (Euroﬁns, Germany). Standard DNA was diluted
logarithmically to create serial standards at 1 3 109 to 1 3 101.
Both standard and experimental DNA were ampliﬁed using
the ABI7300 protocol (Applied Biosystems), and the bacterial
loads, expressed in copies per milliliter were extrapolated from
the cycle threshold values, calculated by using ABI software.
Statistical analysis was performed using the Mann–Whitney
U test. Data are expressed as median with interquartile range
(IQR).
RESULTS
One hundred fourteen study participants in our clinical study
had culture-conﬁrmed pneumococcal meningitis. Of these,
43 had both t 5 0a n dt 5 48 samples available (Table 1). Eight
control patients with headache provided CSF with no evidence
of meningitis. In sum, 28 of 43 study patients survived to
day 10, and 15 died (mortality rate 34.8%); no patients died
in the control group. All patients had therapeutic levels of
ceftriaxone in the CSF, and all isolates were fully sensitive
(mean minimum inhibitory concentration, 0.038 lg/mL;
range, 0.0003–0.19 lg/mL).
Ply and NanA concentrations were measured in all samples.
PlyandNanAweredetectedonlyinthe patient samples(median
Ply, 1.115 mg/mL [IQR, 0.05–0.27]; median NanA, 0.57 lg/mL
[IQR, 0.06–1.04];control samples:Ply, 0 6 0 mg/mL and NanA,
0.0 6 0 lg/mL) (Figure 1A and 1B).
CSF Ply
Survivorshadmedian Plyconcentrationsatt5 0of0.0 3mg /m L
(IQR, 0.01–0.12) and t5 48 hours of 0.01 mg/mL (IQR, 0.0–0.05)
(P 5 .041) (Figure 1C). Nonsurvivors at the same time points
had median Ply concentrations of 0.075 mg/mL (IQR, 0.01–0.13)
and 0.07 mg/mL (IQR, 0.01–0.10) at P 5 .98 (Figure 1C). The
difference between Ply levels at t 5 48 between the survivors
and nonsurvivors was signiﬁcant at P 5 .006.
CSF NanA
Survivors’ CSF samples at t 5 0a n dt 5 48 after antibiotic
treatment had no signiﬁcant difference in their median NanA
concentrations of 0.4 lg/mL (IQR, 0.0–0.7) and 0.2 lg/mL
(IQR, 0.0–0.5), respectively, at P 5 .39 (Figure 1D). The non-
survivors at the same time points had values of 0.3 lg/mL
Table 1. Demographic and Clinical Details of Study Participants
Characteristics Total
Survivors
DEX
Survivors
Placebo
Nonsurvivors
DEX
Nonsurvivors
Placebo
No. of patients 43 20 (46.5%) 8 (18.6%) 8 (18.6%) 7 (16.3%)
HIV-positive 34 (79%) 15 7 5 7
Median age 29 (IQR, 23–36) 27.5 34 31 28
Female 24 (55.8%) 12 4 3 5
Median Glasgow coma
score at presentation
10/15 (IQR, 8–14) 13/15 10.5/15 8.5/15 11/15
CSF WCC, cells/mm
2 640 (IQR, 110–2720) 920 724.5 560 365
CSF protein, trace 5 30 g/L, 115100 g/L,
215500 g/L
21 21 21 21 21
CSF glucose, Neg 5 ,2.8 mmol/L,
trace/1152.8 mmol/L, 2 5 5.5 mmol/L
Neg Neg Trace 32 Trace 31
Serotype of Streptococcus pneumoniae where
known (No. of patients with that serotype)
4 (1) 1 (1) 1 (1) 6 (1)
9 (2) 3 (1) 7 (1)
7 (1) 1 (14)
33 (1)
1 (2)
15 (1)
Abbreviations: CSF, cerebrospinal ﬂuid; DEX, dexamethasone; HIV, human immunodeﬁciency virus; IQR, interquartile range; WCC, white cell count.
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P 5 .56 (Figure 1D).
CSF Bacterial Load by PCR
All CSF samples were sterile by culture at 48 hours. The median
CSF bacterial load measured by PCR copy number was signiﬁ-
cantly reduced at t 5 48 compared with t 5 0 in survivors; t 5 0
copy number was 3.9 3 10
5 copies/mL (IQR, 5.3 3 10
4 to
1.15 3 10
6)a n dt 5 48 copy number was 3.4 3 10
4 (IQR,
1.56 3 10
4 to 8.9 3 10
4)c o p i e s / m La tP , .005 (Figure 1E).
In nonsurvivors the median CSF bacterial copy number at
t 5 0 was 3.6 3 10
5 (IQR, 8.4 3 10
4 to 3.7 3 10
6)a n da t
t 5 48 hours it was 1.3 3 10
5 (IQR, 1.4 3 10 to 5.4 3 10
5)
at P 5 .19 (Figure 1E). The differences in bacterial loads be-
tween survivors and nonsurvivors at admission (P 5 .89) and
48 hours after admission (P 5 .07) were both nonsigniﬁcant.
DISCUSSION
In this study, Ply levels were signiﬁcantly reduced between ad-
mission and 48 hours in survivors but not in nonsurvivors.
Nonsurvivors had higher CSF Ply levels at t 5 0. Levels of NanA
did not change signiﬁcantly between the 2 groups over the
2 time periods. The bacterial load measured by culture was
reduced to zero in both groups. The bacterial load measured
by copy number fell in both survivors and nonsurvivors, with
a signiﬁcant fall only in the survivor group. In the nonsurvivor
group, high levels of Ply persisted and were associated with
a nonsigniﬁcant fall in the number of bacteria present. In the
survivor group Ply fell with bacterial load. NanA levels did not
correlate with bacterial copy number or outcome. The sterili-
zation of CSF in both groups suggests that ceftriaxone caused
effective bacterial killing in both groups as expected. This
study does not explain the persistence of Ply in the nonsurvivor
group but suggests an association with mortality. Absolute
values of Ply do not predict outcome. The lack of statistically
signiﬁcant differences between the admission bacterial load
in survivors and nonsurvivors is in contrast with a larger data
set (82 CSF samples) from Malawi in children [10]a n di s
likely due to the smaller numbers in this study.
Ply levels seen in our study were very high and consistent
with neurotoxicity (median, 1 mg/mL). For comparison, CSF
Ply levels in animal models of pneumococcal meningitis were
20 ng/mL
21 of CSF [4]. Ply levels were also signiﬁcantly higher
than NanA levels in the same patients. This could be due to
the release of Ply upon bacterial lysis. Ply is necessary for mi-
crovascular invasion of pneumococci across the blood-brain
barrier and is a powerful stimulator of the CSF inﬂammatory
response in pneumococcal meningitis [11]. Animals infected with
wild-type pneumococci intracisternally became unwell within
26 hours, whereas animals infected with pneumolysin-deﬁcient
isogenic mutants remained asymptomatic or survived for sig-
niﬁcantly longer. Attenuation of virulence was observed with Ply
and autolysin mutants in other animal studies [12, 13]. The
association of high levels of CSF Ply and patient nonsurvival
is a novel ﬁnding and highlights the crucial role of Ply in path-
ogenesis of meningitis.
NanA in animal models has been shown to have conﬂicting
roles in inﬂammation; one study demonstrated that NanA
mediated pneumococcal invasion of blood-brain barrier endo-
thelial cells 14], and in another NanA deﬁciency was found to
have no inﬂuence on the clinical course of the disease nor had
any effect on systemic bacterial dissemination [13]. Our ﬁndings
suggest NanA does not have a clear pathogenic role in human
pneumococcal meningitis.
In conclusion, we found that all pneumococcal meningitis
patients had greater levels of Ply and NanA than those expected
from extrapolated animal models. The persistence of high levels
of Ply in nonsurvivors despite falling numbers of bacteria sug-
gests that this protein is involved in severe pathogenesis.
Blocking or inhibiting pneumolysin during acute meningitis may
represent a future therapeutic option to improve mortality.
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